Minireviews
Copyright ©The Author(s) 2022.
World J Gastroenterol. May 7, 2022; 28(17): 1768-1780
Published online May 7, 2022. doi: 10.3748/wjg.v28.i17.1768
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 68Ga DOTATATE positron emission tomography/computed tomography transaxial fusion and whole body projection positron emission tomography. A: A normal patient; B: A different patient with well-differentiated pancreatic neuroendocrine tumor with nodal, bone, and liver metastases. Small liver metastases can be seen SUVmax = 10.4 (arrow).
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 70 year old female with abdominal mass (arrow) showing intense 68Ga DOTATATE uptake. Pancreaticoduodenectomy showed a 4 cm well-differentiated (Ki-67 = 5%) pancreatic neuroendocrine tumor. A: 68Ga DOTATATE positron emission tomography (PET) lesion SUVmax = 118; B: Computed tomography (CT); C: PET/CT fusion.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 73 year old female with well-differentiated neuroendocrine tumor (Ki-67 = 6%) and liver metastases with an unknown primary. A: 68Ga DOTATATE positron emission tomography (PET)/computed tomography (CT) fusion and whole-body PET projection confirms multifocal hepatic metastases SUVmax 34.4 with an area of focal decreased DOTATATE avidity (arrow); B: Fluorodeoxyglucose (FDG) PET/CT fusion and whole-body PET shows mismatched focal intense increased FDG uptake SUVmax 9.1 (arrow), suggestive of heterogeneous tumor phenotype with areas of dedifferentiation.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 79 year old female with well-differentiated neuroendocrine tumors, unknown primary, treated with a complete 177Lu-DOTATATE regimen showing mild response. 177Ga-DOTATATE positron emission tomography (PET) computed tomography transaxial fusion and whole body projection PET pre-therapy and post-therapy. A: Pre-therapy; B: Post-therapy. (A; top) Sternal osseous metastases are partially improved (red arrow; B top), and a mediastinal node is resolving (red arrow; paratracheal). (Bottom row) Dominant pelvic nodal mass (A; white arrow) has decreased (B; white arrow) in size 3.3 × 2.1 (previously 3.7 × 2.6), and uptake SUVmax 39.6 (previously 46.8).